metformin has been researched along with lenvatinib in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Chen, J; Dai, L; Liu, L; Liu, Q; Roessler, S; Shi, L; Wei, T; Xiong, L; Yan, L; Yang, J; Zhang, Q; Zhang, W | 1 |
Cen, X; Cheng, Y; Lu, J; Lu, Y; Luo, C; Wang, F; Xie, C; Yin, Z; Zhan, P | 1 |
3 other study(ies) available for metformin and lenvatinib
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Hypoxia-responsive PPARGC1A/BAMBI/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Metformin; PPAR gamma | 2023 |
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Metformin; Phenylurea Compounds; Proto-Oncogene Proteins c-akt | 2023 |